For the quarter ended June 2026, Gilead Sciences (GILD Quick QuoteGILD - Free Report) reported revenue of $7.8 billion, up 10.2% over the same period last year. EPS came in at -$6.75, compared to $2.01 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $7.37 billion, representing a surprise of +5.92%. The company delivered an EPS surprise of +4.53%, with the consensus EPS estimate being -$7.07.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Gilead performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Product Sales- Oncology- Cell Therapy- Tecartus- U.S.: $29 million compared to the $33.34 million average estimate based on three analysts. The reported number represents a change of -29.3% year over year.
• Product Sales- Oncology- Trodelvy- U.S.: $307 million versus the three-analyst average estimate of $282.78 million. The reported number represents a year-over-year change of +37.1%.
• Product Sales- Liver Disease- Sofosbuvir / Velpatasvir- U.S.: $142 million versus the three-analyst average estimate of $140.35 million. The reported number represents a year-over-year change of -22.8%.
• Product Sales- HIV- Other HIV- U.S.: $23 million versus the three-analyst average estimate of $40.24 million. The reported number represents a year-over-year change of -64.6%.
• Product Sales- Liver Disease- Vemlidy- Total: $289 million compared to the $228.53 million average estimate based on four analysts. The reported number represents a change of +14.7% year over year.
• Product Sales- HIV- Odefsey- Total: $239 million versus $232.5 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -19.8% change.
• Revenues- Royalty contract and other revenues: $176 million versus $34.96 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +551.9% change.
• Total product sales- Total: $7.63 billion versus the four-analyst average estimate of $7.3 billion. The reported number represents a year-over-year change of +8.1%.
• Product Sales- Oncology- Cell Therapy- Yescarta- Total: $346 million versus $379 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -12% change.
• Product Sales- HIV- Biktarvy- Total: $3.77 billion versus the four-analyst average estimate of $3.65 billion. The reported number represents a year-over-year change of +6.9%.
• Product Sales- HIV- Symtuza-Revenue share- Total: $138 million versus $121.13 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +11.3% change.
• Product Sales- Veklury- Total: $23 million versus $100.96 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -81% change.

View all Key Company Metrics for Gilead here>>>

Shares of Gilead have returned +1.2% over the past month versus the Zacks S&P 500 composite's +1.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.